Month: December 2021

Development of a systematic evolution platform We began by developing a 96-well plate-based method, wherein 500-µl cultures of evolving M13 bacteriophage (Fig. 1a) are serially diluted with fresh host bacteria twice per hour using an automated liquid handler (Fig. 1b). To enable the pipetting speeds required to approximate continuous flow, we developed a robotic Python
0 Comments
                          Welcome to this week’s Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Kyle LaHucik, and we will feature it here at the end of each week. CRISPR Therapeutics quietly reports R&D chief’s firing in SEC filing CRISPR Therapeutics Tony Ho, M.D., has
0 Comments
A team led by Prof. HU Linhua at the Hefei Institutes of Physical Science of the Chinese Academy of Sciences (CAS) has recently developed a type of self-healing perovskite solar cell by functional combination of polyvinylpyrrolidone (PVP). Related results were published in Journal of Energy Chemistry. A team led by Prof. HU Linhua at the Hefei Institutes of Physical
0 Comments
Ionis’ heart disease drug has had many names over the years, and, now, it has yet another plus a Big Pharma partner in AstraZeneca and billions in potential biobucks possible down the line. The two companies have closed a development and commercialization deal for $200 million upfront, $485 million in additional conditional payments and, last
0 Comments
Russian researchers have developed a strategy to create a cheap and rapid COVID-19 test based on isothermal amplification. According to their publication in Applied Biochemistry and Microbiology, use of this strategy will make it possible to create universal test systems for any of the COVID-19 variants. There are several options for systems that detect traces
0 Comments
Samsung Group is in talks to buy Biogen in a deal that could be worth $42 billion, the Korea Economic Daily reported Wednesday, citing investment banking sources. If the report is true—and if negotiations succeed—Samsung would take control of Biogen at a time when the biotech is laboring to launch its controversial Alzheimer’s drug, Aduhelm,
0 Comments
In a recent study published on the medRxiv* preprint server, researchers carried out an analytical susceptibility test with cultured severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant in seven antigen-detecting rapid diagnostic (Ag-RDTs). Study: Analytical sensitivity of seven SARS-CoV-2 antigen-detecting rapid tests for Omicron variant. Image Credit: Roman Zaeits / Shutterstock.com Background Related Stories
0 Comments
Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA has approved Leo Pharma’s rival antibody tralokinumab. IL-13 inhibitor tralokinumab has been cleared by the US regulator as Adbry as a treatment for moderate-to-severe atopic dermatitis in adults who can’t control symptoms using topical prescription therapies. The
0 Comments
A novel analysis of medical records for a racially diverse group of more than 6,000 women has added to evidence that some combination of biological, social and cultural factors — and not race alone — is likely responsible for higher rates of preeclampsia among Black women born in the United States compared with Black women
0 Comments
Clinical benefits of combining H&E and IHC on the same slide include conservation of small specimens, such as biopsies, to maximize the amount of clinical information obtained from the specimen, and the ability to evaluate protein expression within the full H&E context, bringing to bear the trove of information that H&E based staining provides the
0 Comments
Sanofi is betting $1 billion on a preclinical pipeline of anti-cancer T-cell engagers. The upfront outlay, plus up to $225 million in milestones, is set to give Sanofi ownership of West Coast immuno-oncology player Amunix Pharmaceuticals. Amunix is building a pipeline of T-cell engagers on XPAT, a technology designed to improve the safety of the
0 Comments
An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike protein that remain essentially unchanged as the viruses mutate. By identifying the targets of these “broadly neutralizing” antibodies on the spike protein, it might be possible to design vaccines and antibody treatments
0 Comments
A new preprint* research paper under consideration at Nature Portfolio Journal assesses the susceptibility of the Omicron variant to neutralizing antibody response after booster immunization. Whereas the variant completely escapes the neutralizing activity from doubly vaccinated individuals, convalescent individuals, and different monoclonal antibodies in clinical use, the researchers from Germany showed that a booster vaccine
0 Comments